Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
Kas Steuten, Heeyoung Kim, John C. Widen, et al.
ACS Infectious Diseases (2021) Vol. 7, Iss. 6, pp. 1457-1468
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells
Jana Koch, Zina M. Uckeley, Patricio Doldan, et al.
The EMBO Journal (2021) Vol. 40, Iss. 16
Open Access | Times Cited: 280
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
Naoya Kitamura, M. Sacco, Chunlong Ma, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2848-2865
Open Access | Times Cited: 135
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Koen Vandyck, Jérôme Deval
Current Opinion in Virology (2021) Vol. 49, pp. 36-40
Open Access | Times Cited: 129
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
Chunlong Ma, Zilei Xia, M. Sacco, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 49, pp. 20697-20709
Open Access | Times Cited: 121
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
Hengrui Liu, Sho Iketani, Arie Zask, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
Zongyang Lv, Kristin E. Cano, Lijia Jia, et al.
Frontiers in Chemistry (2022) Vol. 9
Open Access | Times Cited: 75
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
Xiaojing Pang, Wei Xu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115491-115491
Open Access | Times Cited: 57
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
Yanmei Hu, Chunlong Ma, Tommy Szeto, et al.
ACS Infectious Diseases (2021) Vol. 7, Iss. 3, pp. 586-597
Open Access | Times Cited: 93
Perspectives on SARS-CoV-2 Main Protease Inhibitors
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 23, pp. 16922-16955
Open Access | Times Cited: 93
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
Zilei Xia, M. Sacco, Yanmei Hu, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 4, pp. 1408-1421
Open Access | Times Cited: 85
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
Wayne Vuong, Conrad Fischer, Muhammad Bashir Khan, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113584-113584
Open Access | Times Cited: 83
Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation
Woan-Ing Twu, Ji‐Young Lee, Heeyoung Kim, et al.
Cell Reports (2021) Vol. 37, Iss. 8, pp. 110049-110049
Open Access | Times Cited: 83
Metal Complexes as Antiviral Agents for SARS‐CoV‐2
Johannes Karges, Seth M. Cohen
ChemBioChem (2021) Vol. 22, Iss. 16, pp. 2600-2607
Open Access | Times Cited: 72
Enterovirus A71 antivirals: Past, present, and future
Jun Wang, Yanmei Hu, Madeleine Zheng
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1542-1566
Open Access | Times Cited: 71
SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway
Da‐Yuan Chen, Nazimuddin Khan, Brianna J. Close, et al.
Journal of Virology (2021) Vol. 95, Iss. 19
Open Access | Times Cited: 68
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L
Anneliese S. Ashhurst, Arthur H. Tang, Pavla Fajtová, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2956-2970
Open Access | Times Cited: 65
A Charge‐Switchable Zwitterionic Peptide for Rapid Detection of SARS‐CoV‐2 Main Protease
Zhicheng Jin, Yash Mantri, Maurice Retout, et al.
Angewandte Chemie International Edition (2021) Vol. 61, Iss. 9
Open Access | Times Cited: 62
Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors
Julia Stille, Jevgenijs Tjutrins, Guanyu Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114046-114046
Open Access | Times Cited: 60
ReI Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS‐CoV‐2 Main Cysteine Protease
Johannes Karges, Mark Kalaj, Milan Gembický, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 19, pp. 10716-10723
Open Access | Times Cited: 59
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection
Zhifen Cui, Cong Zeng, Furong Huang, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 10, pp. 1056-1064
Open Access | Times Cited: 45
Lysosomal enzyme trafficking: from molecular mechanisms to human diseases
Thomas Braulke, Jan E. Carette, Wilhelm Palm
Trends in Cell Biology (2023) Vol. 34, Iss. 3, pp. 198-210
Closed Access | Times Cited: 24
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 22
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top